Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

5 Cloud Stocks Still Reaching for the Sky, Despite the Pullback

By Thomas Niel, InvestorPlace Contributor

Even when factoring in the recent correction in the tech sector, there's good reason to keep an eye on these five top cloud stocks.

Despite Strong Competition, Don’t Bet Against DraftKings Stock

By Thomas Niel, InvestorPlace Contributor

The launch of Barstool's betting app isn't good for DraftKings stock, but the return of pro football could keep shares steady.

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

By Thomas Niel, InvestorPlace Contributor

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. AstraZeneca (NYSE:AZN) CureVac (NASDAQ:CVAC) GlaxoSmithKline (NYSE:GSK) Inovio (NASDAQ:INO) Johnson & Johnson (NYSE:JNJ) Moderna (NASDAQ:MRNA) Novavax (NASDAQ:NVAX)

Don’t Bother With United Airlines When Low-Cost Carriers Are Better Buys

By Thomas Niel, InvestorPlace Contributor

With a vaccine still in progress, and low-cost airlines better recovery plays, there's little reason to dive into UAL stock right now.

It’s Not Over Yet for Novavax Stock, but Wait for Another Pullback

By Thomas Niel, InvestorPlace Contributor

While factors could change the game, you can't say it's over for NVAX stock. Still, wait for lower prices before diving into high-risk, high-return Novavax.

Load More